(Q37128658)

18 August 2017

1 reference

title

Mathematics for understanding disease (English)

1 reference

18 August 2017

R R Bies

1

1 reference

18 August 2017

M R Gastonguay

series ordinal

2

1 reference

18 August 2017

S L Schwartz

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

26 March 2008

1 reference

Clinical Pharmacology & Therapeutics

18 August 2017

published in

1 reference

18 August 2017

volume

83

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

904-908

1 reference

maintained by WikiProject

18 August 2017

WikiProject Mathematics

1 reference

Drug treatment effects on disease progression.

inferred from title

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Using Disease Progression Models as a Tool to Detect Drug Effect

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Disease system analysis: basic disease progression models in degenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Orchestration of glucose homeostasis: from a small acorn to the California oak

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Blood pressure control--special role of the kidneys and body fluids

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Meal simulation model of the glucose-insulin system

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Cancer as a robust system: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Fractal mechanisms in the electrophysiology of the heart.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Use of wavelet and fast Fourier transforms in pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Model-based development of gemcabene, a new lipid-altering agent

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.53

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.53

1 reference

18 August 2017

1 reference